Management of peritoneal metastases from colorectal cancer and small bowel adenocarcinoma in patients with inflammatory bowel disease

Table 1 Baseline clinical characteristics of patients with peritoneal metastases undergoing cytoreductive surgery with hyperthermic intraperitoneal chemotherapy comparing inflammatory bowel disease and non-inflammatory bowel disease cohorts across two studies

Feature	Ben-Yaacov et al[45], 2024		Hammoudi et al[21], 2018
	IBD cohort (n = 10)	Non-IBD cohort (n = 222)
Primary tumor site	30% small bowel primaries	100% colorectal	50% small-bowel, 50% colon/rectum
ASA score1	Lower (P = 0.005)	Higher	Not reported
Hypertension	Less frequent (P = 0.033)3	More frequent	Not reported
Prior abdominal surgery	Universal (IBD management)	Variable	50% prior resections for IBD
Surveillance colonoscopy2	N/A		Only 2/14 had routine surveillance

¹American Society of Anesthesiologists physical status classification score: Lower values indicate fewer systemic comorbidities.

²Surveillance colonoscopy indicates routine endoscopic monitoring prior to diagnosis.

³P values refer to comparisons between inflammatory bowel disease and non- inflammatory bowel disease cohorts; P < 0.05 considered statistically significant. When P values are non-significant yet sample sizes are small, interpret with caution due to limited statistical power.

IBD: Inflammatory bowel disease; ASA: American Society of Anesthesiologists physical status classification; N/A: Not applicable.